Article
Biomarkers of NAFLD progression: a lipidomics approach to an epidemic.
Journal of lipid research - 1 Mar 2015
Gorden D Lee, Myers David S, Ivanova Pavlina T, Fahy Eoin, Maurya Mano R, Gupta Shakti, Min Jun, Spann Nathanael J, McDonald Jeffrey G, Kelly Samuel L, Duan Jingjing, Sullards M Cameron, Leiker Thomas J, Barkley Robert M, Quehenberger Oswald, Armando Aaron M, Milne Stephen B, Mathews Thomas P, Armstrong Michelle D, Li Chijun, Melvin Willie V, Clements Ronald H, Washington M Kay, Mendonsa Alisha M, Witztum Joseph L, Guan Ziqiang, Glass Christopher K, Murphy Robert C, Dennis Edward A, Merrill Alfred H, Russell David W, Subramaniam Shankar, Brown H Alex
Abstract excerpt
The spectrum of nonalcoholic fatty liver disease (NAFLD) includes steatosis, nonalcoholic steatohepatitis (NASH), and cirrhosis. Recognition and timely diagnosis of these different stages, particularly NASH, is important for both potential reversibility and limitation of complications. Liver biopsy remains the clinical standard for definitive diagnosis. Diagnostic tools minimizing the need for invasive procedures...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.